Olaparib

Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership OSLO, Norway and CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the appointment of Steven Kelly as Chief Executive Officer and a member of its Board of Directors, alongside the appointment of Briggs Morrison as Chair of the Board and John Crowley as an independent director. The appointments strengthen Actithera’s leadership team as the company advances into clinical development and enters its next phase of growth. As Chief Executive Officer, Mr. Kelly will lead Actithera as it progresses its lead fibroblast activation protein (FAP)-targeted RLT into clinical development and continues to build its pipeline of differentiated radiopharmaceuticals. Founder Andreas Goutopoulos will continue as President and Head of Research & Development, leading Actithera’s scientific vision, medicinal chemistry platform, research organization, and discovery pipeline. Dr. Briggs Morrison, Chair of the Board of Actithera, said: “Actithera has reached an important inflection point as it prepares to translate a differentiated scientific platform into clinical development. Andreas and the team have built a strong scientific foundation, and Steve brings the company-building and operating experience needed to lead Actithera through this next phase. Together with John’s financial and strategic expertise, our strengthened leadership team brings together the capabilities Actithera needs to execute with discipline and build on the Company’s momentum.” Mr. Kelly brings more than 30 years of biotechnology leadership experience spanning company building, corporate strategy, business development and commercialization. He most recently served as President, Chief Executive Officer and a director of Carisma Therapeutics, where he led the company from an academic platform to a publicly traded, clinical-stage biotechnology company, raising more than $300 million in financing and establishing collaborations with leading global biopharmaceutical companies. Earlier in his career, Mr. Kelly held senior leadership roles at BioVex, Sanofi, IDEC Pharmaceuticals and Amgen, contributing to the commercialization of several landmark oncology therapies. Mr. Steven Kelly, Chief Executive Officer of Actithera, said: “Actithera has differentiated science, a highly experienced team, and a clear opportunity to address important limitations in radioligand therapy for patients. Our priorities are clear: advance the lead FAP-targeted program into clinical development, continue building the pipeline behind it, and establish the capabilities needed to execute with rigor and discipline. I look forward to working alongside the team to translate our scientific foundation into clinical progress and ultimately deliver new treatment options for patients with significant unmet needs.” Dr. Andreas Goutopoulos, Founder, President and Head of Research & Development of Actithera, said: “I founded Actithera on the conviction that innovative chemistry could be applied to address fundamental limitations of radioligand therapy. It has been a privilege to build a team that has transformed those ideas into a powerful platform, a growing pipeline, and a lead program approaching clinical development. Steve brings valuable experience at this important stage of our development, and I’m excited to work alongside him as we enter the next phase and continue advancing the science.” Mr. Crowley brings more than 30 years of financial and strategic leadership experience across the biotechnology industry. He most recently served as Chief Financial Officer of Centessa Pharmaceuticals, where he helped lead the company’s strategic transformation ahead of its $7.8 billion acquisition by Eli Lilly. Previously, as Chief Financial Officer of Fusion Pharmaceuticals, he helped build one of the radioligand industry’s leading companies from early development through its Nasdaq initial public offering and subsequent acquisition by AstraZeneca. Throughout his career, he has raised more than $1.5 billion in capital and brings deep experience in capital markets, corporate strategy, business development, and public company governance. Dr. Morrison is Chief Executive Officer of Crossbow Therapeutics, Chair of Arvinas and a member of the board of directors of CRISPR Therapeutics. A medical oncologist with more than 30 years of experience in the pharmaceutical and biotechnology industries, he previously held executive leadership positions at Syndax Pharmaceuticals, AstraZeneca, Pfizer and Merck, where he oversaw the clinical development of numerous oncology medicines, including Tagrisso ® , Imfinzi ® and Lynparza ® . For further information: Optimum Strategic Communications Mary Clark, Isabelle Abdou, Katie Flint Tel: +44 20 3922 1906 Email: actithera@optimumcomms.com About Actithera Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. In July 2025, the Company raised a $75.5 million Series A financing backed by blue chip investors, to advance its pipeline and accelerate clinical development of its lead FAP-targeting radioligand therapy, with a focus on addressing critical unmet needs in oncology. Learn more at and on LinkedIn .

Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed Imfinzi (durvalumab) plus Amgen’s Imdelltra® (tarlatamab) demonstrated a statistically significant and highly clinically meaningful improvement in overall survival (OS) versus Imfinzi alone as a 1st-line maintenance treatment. The trial included patients with extensive-stage small cell lung cancer (ES-SCLC) who had not progressed following standard induction treatment with Imfinzi in combination with platinum chemotherapy (investigator’s choice of carboplatin or cisplatin) and etoposide. Imfinzi plus tarlatamab also demonstrated a statistically significant and clinically meaningful improvement in the secondary endpoints of progression-free survival (PFS) and objective response rate. In 2026, an estimated 195,000 people globally will be treated for ES-SCLC, a highly aggressive, fast-growing form of lung cancer characterised by rapid tumour progression and metastatic spread to organs such as the brain and liver.1,2 Immune checkpoint inhibitors such as Imfinzi have led to significant improvements in OS in ES-SCLC, establishing a 1st-line standard of care. However, many patients still experience disease progression due to the aggressive nature of the disease and median OS with the current standard of care is approximately one year.3 Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “These results show that Imfinzi-based induction therapy followed by maintenance treatment with Imfinzi plus tarlatamab demonstrates an unprecedented improvement in overall survival for patients with this highly aggressive form of lung cancer. Imfinzi continues to reshape how lung cancer is treated, establishing new standards of care across multiple settings, and these new findings further underscore its role as the backbone immunotherapy of choice for small cell lung cancer.” Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, said: “Given the aggressive nature of small cell lung cancer, many patients quickly relapse on current therapy and never reach second-line treatment. These patients do not have time to wait, making substantial progress in the first-line setting critically important. In my career treating people with extensive-stage small cell lung cancer, these are among the most compelling survival results I have seen, indicating the potential to reshape the natural history of small cell lung cancer. DeLLphi-305 represents an unprecedented milestone and suggests we may be entering a new era where meaningfully longer survival is possible for more patients.” Overall, the safety and tolerability profile of Imfinzi plus tarlatamab was consistent with the known safety profiles of the individual treatments, with no new safety signals identified. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. Imfinzi is approved in the US, EU, Japan, China and many other countries around the world as the standard-of-care treatment for ES-SCLC and limited-stage SCLC (LS-SCLC) based on the CASPIAN and ADRIATIC Phase III trials, respectively. Notes Small cell lung cancer Lung cancer is the leading cause of cancer death globally, accounting for almost one in five (19%) cancer deaths.4,5 Lung cancer is broadly split into non-small cell lung cancer (NSCLC) and SCLC, with about 15% classified as SCLC.6 About two-thirds of SCLC patients are diagnosed with ES-SCLC, in which the cancer has spread widely through the lung or to other parts of the body.3 While survival rates have improved in recent years following the introduction of immune checkpoint inhibitors, prognosis is still poor, with only 18.1% of LS-SCLC patients and 3.6% of ES-SCLC patients alive five years after diagnosis.2 DeLLphi-305 The DeLLphi-305 trial is sponsored by Amgen, with partial funding and Imfinzi provided by AstraZeneca. It is a global Phase III, randomised, open-label clinical trial evaluating the efficacy and safety of Imfinzi in combination with tarlatamab compared to Imfinzi alone as 1st-line maintenance treatment for patients with ES-SCLC who have not progressed following induction treatment with Imfinzi in combination with platinum chemotherapy and etoposide. Tarlatamab is a first-in-class targeted immunotherapy that binds to both DLL3 on tumour cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC cells. DLL3 is a protein that is expressed on the surface of SCLC cells in ~85-96% of patients with SCLC, but is minimally expressed on healthy cells. In the trial, 563 patients who completed Imfinzi-based induction treatment were randomised 1:1 to receive either Imfinzi in combination with tarlatamab or Imfinzi alone until progression or unacceptable toxicity. Following tarlatamab infusion on Cycle 1 Day 1 and Cycle 1 Day 8, patients were monitored in a healthcare setting for 1 to 2 hours (6 to 8 hours in certain regions including Europe). The trial included patients with both treated and untreated asymptomatic brain metastases at baseline. The primary endpoint is OS for Imfinzi plus tarlatamab versus Imfinzi alone. PFS is a key secondary endpoint. Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. In addition to its indications in SCLC, Imfinzi is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy (CRT). Additionally, Imfinzi is approved as a perioperative treatment in combination with neoadjuvant chemotherapy in resectable NSCLC, and in combination with a short course of Imjudo (tremelimumab) and chemotherapy for the treatment of metastatic NSCLC. Imfinzi is also approved in combination with chemotherapy in locally advanced or metastatic biliary tract cancer and in combination with Imjudo in unresectable hepatocellular carcinoma (HCC). It is also approved as a monotherapy in unresectable HCC in Japan, China and the EU, and in resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers in the US and the EU. Additionally, in April 2026, Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolisation (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS versus TACE alone for patients with unresectable HCC eligible for embolisation in the EMERALD-3 Phase III trial. Perioperative Imfinzi in combination with neoadjuvant chemotherapy is approved for cisplatin-eligible muscle-invasive bladder cancer (MIBC). Imfinzi in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy is approved in the US and other countries for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer. In May 2026, positive high-level results from the VOLGA Phase III trial showed that perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and OS in patients with MIBC who were ineligible for or had declined cisplatin-based chemotherapy. In addition, perioperative Imfinzi plus Imjudo in combination with neoadjuvant EV demonstrated a statistically significant and clinically meaningful improvement in EFS and a favourable trend for OS; however, the OS data were not statistically significant at this planned interim analysis and will be formally reassessed at a subsequent analysis. In July 2026, positive high-level results from the NILE Phase III trial showed Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS versus chemotherapy as 1st-line treatment for patients with PD-L1 high unresectable, locally advanced or metastatic urothelial cancer. Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy is approved as a 1st-line treatment for primary advanced or recurrent endometrial cancer (mismatch repair deficient disease only in US, EU and China). Imfinzi in combination with chemotherapy followed by Lynparza (olaparib) and Imfinzi is approved for patients with mismatch repair proficient advanced or recurrent endometrial cancer in EU and Japan. Since the first approval in May 2017,more than 470,000 patients have been treated with Imfinzi. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with NSCLC, bladder cancer, breast cancer, ovarian cancer and several gastrointestinal cancers. AstraZeneca in lung cancer AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most. The Company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action. AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment. AstraZeneca in immuno-oncology (IO) AstraZeneca is a pioneer in introducing the concept of immunotherapy into dedicated clinical areas of high unmet medical need. The Company has a comprehensive and diverse IO portfolio and pipeline anchored in immunotherapies designed to overcome evasion of the anti-tumour immune response and stimulate the body’s immune system to attack tumours. AstraZeneca strives to redefine cancer care and help transform outcomes for patients with Imfinzi as a monotherapy and in combination with Imjudo as well as other novel immunotherapies and modalities. The Company is also investigating next-generation immunotherapies like bispecific antibodies and therapeutics that harness different aspects of immunity to target cancer, including cell therapy and T-cell engagers. AstraZeneca is pursuing an innovative clinical strategy to bring IO-based therapies that deliver long-term survival to new settings across a wide range of cancer types. The Company is focused on exploring novel combination approaches to help prevent treatment resistance and drive longer immune responses. With an extensive clinical programme, the Company also champions the use of IO treatment in earlier disease stages, where there is the greatest potential for cure. AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death. AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References Matthew Bowden Company Secretary AstraZeneca PLC Oncology Corporate and financial